Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key ...

Purple Biotech shares soared in premarket trading Monday after the company reported positive phase two study results for its pancreatic cancer drug Shares traded 68% higher at $5.63.

Relay Therapeutics faces challenges with limited clinical data and high expenses but shows promise with their 4D drug design ...

The biotech, which has been working towards commercial development of its IP since March 2022, is targeting ASX quotation in ...

And former federal health minister Greg Hunt is a board director. The post ASX IPO watch: Aspiring healthcare stock has ...

Biotech HaemaLogiX – which counts former health minister Greg Hunt as a director – is preparing a 2025 ASX listing, as it ...

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going ...

HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

In August last year, Zibo Tianheng New Nanomaterials Technology said failure to conduct an IPO by the end of 2023 could ...

Research and Development (R&D) expenses were $9.7 million for the third quarter of 2024 compared to $9.8 million for the third quarter of 2023. The decrease was mainly due to a modest reduction in ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

Central government’s focus to reform the Public Distribution System (PDS) has led to removal of 5.8 Crore ration cards from ...